Plain-English translation of NCT06961617 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called LioCyx-M, which uses your own immune cells that have been specially engineered in the lab to recognize and fight liver cancer. The cells are trained to target a protein from hepatitis B that appears on cancer cells. Researchers will give you weekly infusions of these cells to see if they can shrink your tumor and are safe to use.
Many people with hepatitis B-related liver cancer find that standard treatments like surgery or chemotherapy stop working or aren't an option for them. This medication represents a new approach using your body's own immune system to attack the cancer, offering hope for patients who have run out of other choices.
You likely qualify if…
You likely don't qualify if…
You would receive weekly infusions of the engineered immune cells at the study center, with each dose tailored to your body weight. The trial will monitor you closely for safety, checking how well your body tolerates the treatment and whether your cancer responds. This is a phase 1 trial with a small group of about 10 patients, so the main focus will be on gathering safety data and early signs of effectiveness.
AI-generated summary from trial data · Jul 14, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Lion TCR Pte. Ltd.
Collaborators
Beijing GoBroad Hospital
Enrollment target
~10 participants
Started
June 2024
Primary completion
December 2027
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wang Zhe
Lion TCR Pte. Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.